In this video from Tuesday's Market Checkup, Motley Fool health-care analyst David Williamson takes investors through the biggest investing stories in the health care space today.

In this segment, David takes a look at two of the day's losers from the world of health care. Animal health powerhouse Zoetis (NYSE:ZTS) fell 5% today, after it reported fourth-quarter results that came in slightly ahead of analyst estimates, at $0.36 per share versus an estimate of $0.34. However, the news that had shares falling was the company's guidance for 2014. With a midpoint of $1.51 in per-share 2014 earnings, guidance was 10 cents lighter per share than analysts had hoped, and the stock took a haircut as a result.

Small-cap active pharmaceutical ingredient maker Cambrex (NYSE:CBM) is today's other loser. While there was no further clarity regarding rumors over the a possible deal for Cambrex regarding the hepatitis C drug Sovaldi, the more important factor today was that the company released guidance for 2014, which, like Zoetis, was also lower than estimates.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.